Would you choose bimekizumab over other IL-17 inhibitors in patients with increased levels of disease related pain and poor functional status?

In the absence of head-to-head trials, I hesitate to make a recommendation regarding which IL 17 inhibitor is better in this situation. It is also very unlikely that the makers of the three IL 17 inhibitors would conduct such trials. Network meta analysis and matching-adjusted indirect comparison are some statistical ways of finding an indirect answer to this question.

Would not prefer Bimekizumab over other IL-17 inhibitors.